A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002 (Anti-Pd-l1 X VEGF-A Bispecific Antibody) in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer